Dr. Lisa Yanoff has a very expensive problem on her desk. She is the FDA deputy director looking at Foundayo. This is Eli Lilly’s new weight-loss pill. It was approved in record time. Now, the government wants more data. They are worried about liver damage and heart risks. They especially want to know what it does to teenagers. Foundayo is the latest weapon in the war for the Subscription Body.

Lilly is currently winning the marketing race. Their oral drug is cheaper and easier than injections. They just released data from the ACHIEVE-4 trial. It shows that Foundayo cut the risk of death by 57 percent in some patients. That is a massive number. It makes the drug look like a miracle. But the FDA isn't satisfied with miracles. They want clinical trials on gastroparesis and liver toxicity. They are demanding post-marketing studies to see the real cost of being thin.

Meanwhile, Novo Nordisk is fighting back with its own pill version of Wegovy. BioSpace reports that Novo might have a muscle advantage. Their drug seems to preserve lean mass better than Lilly's version. It is a battle of the balance sheets. The elite are choosing their pharma brand like they choose their watches. In this economy, a flat stomach is the ultimate status symbol.